Comparative Efficacy of Pregabalin and Lacosamide in Patients With Herpes Zoster and Post Herpetic Neuralgia
NCT ID: NCT06969417
Last Updated: 2025-05-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
50 participants
INTERVENTIONAL
2025-04-10
2025-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Pregabalin is a gabapentinoid licenced for treatment of neurological disorders. It is one of the earlier drugs approved by the US Food and Drug Administration (2004) for the treatment of painful diabetic neuropathy and postherpetic neuralgia (PHN). Lacosamide (LCM) was approved in 2008 in the European Union and in the United States as adjunctive therapy for the treatment of focal-onset seizures with or without secondary generalization in adults and adolescents with epilepsy. Its efficacy has also been proven in neuropathic pain.
Although Pregabalin and Lacosamide have proven effective in various neuropathic pain disorder, comparative studies specifically for PHN remain scarce. This study aims to compare the efficacy of Pregabalin and Lacosamide in PHN patients, addressing the current gap in literature and providing clinically relevant insights to optimize treatment selection.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy of Pregabalin for the Treatment of Acute Herpetic Neuralgia
NCT03809702
A Study To Compare Pregabalin/PF-00489791 Combination Versus Pregabalin Alone In Post-Herpetic Neuralgia
NCT00599638
Comparison of Oxcarbazepine Versus Carbamazepine in the Management of Trigeminal Neuralgia
NCT06849219
Effect of Early Use of Oxycodone During the Acute Phase of Herpes Zoster on Preventing Postherpetic Neuralgia
NCT03120962
Study to Find Out if Therapy With the Drug Pregabalin Relieves Pain During Shingles Compared With Placebo
NCT00352651
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A
Group A will receive Cap Pregabalin, the first intervention
Pregabalin
o Group A will receive Cap Pregabalin 150mg oral OD for 4 weeks
Group B
Group B will receive Tab Lacosamide
Lacosamide
o Group B will receive Tab Lacosamide 100mg oral BD for 4 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pregabalin
o Group A will receive Cap Pregabalin 150mg oral OD for 4 weeks
Lacosamide
o Group B will receive Tab Lacosamide 100mg oral BD for 4 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Ages: 18 to 50
* Both male and female
Exclusion Criteria
* Patient already taking pain killers for post herpetic neuralgia
* Patients suffering from other systemic illness
18 Years
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
CMH Kharian Medical College
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mushayada Irshad
Dr Mushayada Irshad
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Usman Nawaz, MBBS, Mphil, PhD Pharmacology
Role: STUDY_CHAIR
CMH Kharian Medical College
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CMH Kharian Medical College
Kharan, Punjab Province, Pakistan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CKMC/IERB/AC-00225
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.